Thus, we conducted a Phase Ib clinical study with the HDAC inhibitor vorinostat and the PD‐1 inhibitor pembrolizumab in patients (pts) with metastatic urothelial (UC), renal (RCC) and prostate (PCA) carcinoma. This evidence concerns the gene HDAC9 and medical procedure.